e-Therapeutics plc
('e-Therapeutics' or 'the Company')
Issue of equity
22 May 2014, Oxford and Newcastle, UK: e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces that the Company has today issued 125,000 ordinary shares of 0.1p each in the Company in order to satisfy the exercise of certain options by a former employee.
Application has been made to admit the new ordinary shares to trading on AIM and dealings in the new ordinary shares are expected to commence on 29 May 2014. Following admission the number of Ordinary Shares in the Company in issue will be 264,006,443. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the Financial Conduct Authority's Disclosure and Transparency Rules.
Contacts:
e-Therapeutics plc
Steve Medlicott, Finance Director
Tel: +44 (0) 1993 883125
Panmure Gordon (UK) Limited
Fred Walsh / Duncan Monteith
Tel: +44 (0) 20 7886 2500